Related Experiment Video
Updated: Mar 19, 2026
06:34
Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
Published on: November 29, 2024
671
Dulaglutide (Trulicity): The Third Once-Weekly GLP-1 Agonist.
P & T : a Peer-Reviewed Journal for Formulary Management
|June 18, 2016
Summary
Dulaglutide (Trulicity) is a new once-weekly medication for type-2 diabetes. It belongs to the glucagon-like peptide-1 (GLP-1) receptor agonist class, offering another treatment option.
Area of Science:
- Endocrinology
- Pharmacology
- Metabolic Diseases
Background:
- Type-2 diabetes mellitus (T2DM) is a growing global health concern.
- Effective glycemic control is crucial for preventing T2DM complications.
- Glucagon-like peptide-1 (GLP-1) receptor agonists represent a significant therapeutic advancement.
Purpose of the Study:
- To introduce dulaglutide (Trulicity) as a novel therapeutic agent for T2DM.
- To highlight its unique characteristic as a once-weekly administered GLP-1 receptor agonist.
- To position dulaglutide within the existing treatment landscape for T2DM.
Main Methods:
- Review of preclinical and clinical data for dulaglutide.
- Comparison of dulaglutide's pharmacokinetic and pharmacodynamic profiles with other GLP-1 receptor agonists.
- Analysis of efficacy and safety data from pivotal trials.
Main Results:
- Dulaglutide demonstrated significant reductions in HbA1c levels.
- Once-weekly dosing regimen was found to be convenient for patients.
- Adverse event profile was consistent with the GLP-1 receptor agonist class.
Conclusions:
- Dulaglutide is an effective and well-tolerated option for managing T2DM.
- Its once-weekly administration enhances patient adherence and convenience.
- Dulaglutide represents the third GLP-1 receptor agonist available for T2DM treatment.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
1.2K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.2K
01:06Oral Hypoglycemic Agents: Glinides
897
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
897
01:23Dipeptidyl Peptidase 4 Inhibitors
957
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
957
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
891
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
891
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
823
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
823
01:17Oral Hypoglycemic Agents: Sulfonylureas
1.6K
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
1.6K